The inextricable link between a high cholesterol diet and colon cancer

In a study of mice, scientists from the University of California, Los Angeles, David Geffen School of Medicine found that raising cholesterol levels in animals caused intestinal stem cells to divide faster, increasing tumor formation by 100 times. This study identified a molecular pathway that could serve as a new drug target for colon cancer treatment.

Cholesterol affects the growth of intestinal stem cells, which in turn accelerates the formation of tumors by more than 100 times. Although the link between cholesterol in the diet and colon cancer has been established, no one has previously explained the mechanism behind it. Scientists increased cholesterol in some intestinal stem cells of mice by introducing more substances into the diet. In another study, the researchers changed a gene that regulates phospholipids, which are the main type of fat in cell membranes, prompting cells to produce more cholesterol themselves.

Stem cells have increased reproductive capacity in both groups. As cholesterol levels increase, their cells divide more rapidly, making the intestines longer, and these changes significantly accelerate the rate of tumor formation in the colon.

Susan Hau

Website |  + postsBio ⮌

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

• Susan Hau

  https://cancerfax.com/author/susan/

  Datopotamab deruxtecan-dlnk is approved by the USFDA for EGFR-mutated non-small cell lung cancer
• Susan Hau

  https://cancerfax.com/author/susan/

  PiggyBac Transposon System: A Revolutionary Tool in Cancer Gene Therapy
• Susan Hau

  https://cancerfax.com/author/susan/

  Neoadjuvant and adjuvant pembrolizumab is approved by the USFDA for resectable locally advanced head and neck squamous cell carcinoma
• Susan Hau

  https://cancerfax.com/author/susan/

  Taletrectinib is approved by the USFDA for ROS1-positive non-small cell lung cancer

• Comments Closed
• May 7th, 2020